Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Could cost-saving Crohn's theranostic dent anti-TNF sales for Abbvie, Merck?

This article was originally published in Scrip

Executive Summary

Theradiag's Lisa-Tracker test for monitoring how well Crohn's disease patients are responding to tumor necrosis factor inhibitors, an expensive class of biologics, has shown it could potentially cut hospital spending on these drugs by up to 25% in France alone. While this spells good news for budget-conscious healthcare payers, it may not be as warmly received by the likes of Merck and Abbvie, whose respective anti-TNF products – Remicade (infliximab) and Humira (adalimumab) – are significant cash cows generating billions of dollars in revenue.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts